Bausch + Lomb Corporation (BLCO), the eye health specialist carved out from Bausch Health Companies back in 2022, has been navigating a tricky landscape since its public debut. As everyday investors, we’re often drawn to consumer-facing names like this one—think contact lenses, eye drops, and surgical gear that touch millions of lives daily. But beneath the surface, BLCO’s story is one of steady top-line growth clashing with profitability hurdles, hefty debt from its spin-off, and a stock that’s hovered in a familiar range. With revenue projections pointing to continued expansion and insiders showing fresh confidence, let’s break it down in plain terms, spotting the trends, correlations, and what it might mean for your portfolio.
Revenue Momentum: A Bright Spot Amid Volatility
One of the clearest positives here is revenue growth, which has been a consistent driver. Starting from $3.41 billion in 2020, sales climbed to $3.77 billion in 2021—a solid 10% increase—before holding steady in 2022 at the same level. Then came acceleration: 10% up to $4.15 billion in 2023 and a stronger 15% jump to $4.79 billion in 2024. This isn’t just numbers on a spreadsheet; revenue per employee (a key efficiency metric) has surged from about $301,000 in 2021 to $355,000 in 2024, signaling smarter operations even as headcount grew modestly from 12,500 to 13,500 employees.
Why does this matter? In a mature industry like vision care, where Bausch + Lomb holds strong positions in contacts (e.g., Biotrue) and pharma (e.g., Xiphias for dry eye), sustained revenue growth correlates directly with market share gains and pricing power. Analysts project this continues: 6% annual growth to $5.08 billion in 2025, $5.38 billion in 2026, and $5.68 billion in 2027. Revenue per share echoes this, rising from $13.62 in 2024 to $16.05 by 2027. If history holds—like the post-spin-off push in consumer and surgical segments—this could fuel long-term compounding for shareholders.
That said, gross margins have wobbled around 60% (62.3% in 2020 down to 60.9% in 2024), a decent level for med devices but pressured by supply chain snags from the pandemic era and R&D spend. It’s stable enough to support scalability, but any margin erosion could pinch future profits.
Profitability Struggles and the Path to Black Ink
Digging deeper, earnings tell a bumpier tale. Earnings per share (EPS) flipped from a tiny $0.02 profit in 2022 to losses of -$0.74 in 2023 and -$0.90 in 2024—correlating with EBT margins tanking from positive single-digits pre-2023 to -4.9% last year. Net income swung to red ink too: -$305 million in 2024, a 23% worsening from 2023’s -$248 million loss. These stem from one-offs like restructuring post-spin-off and higher interest costs, but they’re red flags for ROE, which cratered to -4.7% in 2024 from near-zero levels earlier.
Cash flow per share offers some reassurance, rebounding to $0.66 in 2024 from negative territory, though free cash flow per share remains negative at -$0.17. Operating cash flow dropped sharply to just $232 million in 2024 from $873 million in 2021—a 73% decline—partly due to capex ramping up (from -$181 million in 2023 to -$291 million in 2024, or 61% higher spend). This ties into investments in growth areas like Xiidra (acquired in 2023 for dry eye, a major tailwind amid a booming allergy market).
The good news? Projections flip the script: EPS turns positive at $0.02 in 2025, $0.40 in 2026, and holds there. ROA improves to 2.8% by 2026, ROE to 7.1%. If revenue hits those marks and margins stabilize, BLCO could mirror peers like CooperVision in delivering 5-10% net margins by decade’s end. A pivotal event was the 2022 spin-off from Bausch Health (formerly Valeant, scarred by 2015-2016 scandals over drug pricing), which let BLCO focus purely on ophthalmology—freeing it from legacy debt baggage, though not entirely.
Balance Sheet Realities: Debt Looms Large
No discussion skips the elephant: debt. Total debt exploded post-spin-off, from $2.44 billion in 2022 to $4.56 billion in 2023 (87% surge) and $4.78 billion in 2024 (5% up). Net debt sits at a hefty $4.47 billion, pressuring ROIC to a low 0.9% in 2024. Book value per share has eroded from $28.54 in 2020 to $18.60 in 2024 (35% drop), reflecting share dilution (outstanding shares up 1% to 352 million) and losses.
This leverage amplifies risks—interest eats into EBT, evident in the 2023-2024 profitability dive—but also boosts returns if growth pans out. EV/Sales at 2.26x in 2024 (down from 2.45x prior year) is reasonable for a grower, and projections dip to 1.81x by 2027, hinting at deleveraging potential. Shareholder equity shrank to $6.54 billion in 2024 (5% down YoY), but working capital buffers at $1.05 billion provide some cushion. Correlation here? High debt coincides with stock’s range-bound trading, as investors price in refinancing risks amid rising rates since 2022.
Stock Performance: Steady But Sideways
BLCO’s shares have traced a resilient path since IPO. In 2022, it swung from a low of around 12 to a high of 20—a 65% peak-to-trough spread reflecting spin-off hype fading into reality. 2023 saw 15-22 (46% range), and 2024 dipped to 13-22 (67% volatility), mirroring revenue beats offset by loss reports. Versus fundamentals, the stock decoupled from plunging EPS (PS ratio fell to 1.33x from 1.86x in 2021), trading more on revenue trajectory and eye care tailwinds like aging populations and premium lenses.
PE ratios are wonky due to losses—negative or sky-high like 774x projected for 2026—but PB at 0.97x in 2024 screams undervaluation if book value stabilizes. Compared to the S&P 500’s post-2022 rally, BLCO lagged, but it’s held above 2022 lows despite macro headwinds (inflation hitting consumer discretionary).
Insider Confidence: A Bullish Signal
Insiders aren’t fleeing—they’re buying. In May 2025, a director snapped up 1,695 shares and the CEO/COB grabbed 22,000 shares, totaling nearly $268,000 in purchases. Zero sells across 2025-early 2026 months. This aligns with revenue upticks and profitability inflection; CEOs buying often precedes turnarounds (think how it signaled bottoms for names like Peloton post-COVID). No activity elsewhere suggests quiet accumulation, correlating with analyst upgrades on growth.
Analyst Outlook and Price Targets
Wall Street’s take? The consensus mean target sits right at fair value versus today’s close—0% implied upside—with a high 24% above current levels and low 24% below. This spread reflects debate: bulls bet on 6% revenue CAGR and EPS ramp (Xiidra synergies, international expansion), bears fret debt maturities (some due 2026-2027) and competition from Alcon or Johnson & Johnson Vision.
EV/FCF projections improve dramatically, from negative to supportive levels, backing the high-end optimism. In context, if BLCO hits 2027 revenue and FCF rebounds to $668 million (projected for 2026), it could justify 20%+ rerating.
Looking Ahead: Growth with Guardrails
BLCO’s future hinges on execution. Anticipate mid-single-digit revenue growth through 2027, driven by consumer (60% of sales) and pharma segments, plus capex yielding higher output. Profitability returns as EBT swings positive to $146 million in 2026 (from near-zero), aided by cost cuts and no more spin-off noise. Debt’s the wildcard—refinancing at lower rates (post-Fed cuts?) could unlock 10-15% ROE.
Risks? Macro slowdown crimps elective surgeries; generics erode pharma edges. But major tailwinds like M&A (post-Xiidra) and demographics favor bulls. Versus IPO hype, the stock’s matured into a value play—trading near book, with insider buys and flat targets signaling stability, not fireworks.
For retail investors, BLCO fits a “patient growth” bucket: buy dips if debt fears overblow, hold for 5-7% yields via compounding sales. It’s not a moonshot, but in eye health—a recession-resistant $40B+ market—it’s positioned for steady gains. Watch Q1 2026 earnings for FCF traction; that could spark the next leg up. (Word count: 1,128)